http://rdf.ncbi.nlm.nih.gov/pubchem/reference/34049818

Outgoing Links

Predicate Object
contentType Letter|Research Support, Non-U.S. Gov't
endingPage 206
issn 1365-2141
0007-1048
issueIdentifier 1
pageRange 203-206
publicationName British Journal of Haematology
startingPage 203
bibliographicCitation Manson G, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Regny C, Bouabdallah K, Chauchet A, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Dercle L, Brice P, Houot R; Lymphoma Study Association (LYSA). Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA). Br J Haematol. 2022 Jul;198(1):203–6. doi: 10.1111/bjh.18198. PMID: 35445392.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d8f78cf6d019c940b48aa5f39434ce70
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a5bab29fbf10551ab8451d43666625ea
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3131-3718
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-1430-2574
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef7d8ec20c4121fff7abcfbb42485c51
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7468-5466
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3e9994da70b9bb04c6d8ed82e4d59dde
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccfb6d63a994e2b9f480ebae450f7d26
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b7d8ee73c42871f0dd59c2338b1fd833
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-4280-7825
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0a1e777e5d8b857a2012bd93c8b8f5a9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_55bb414ee14a3587ab5bcd6a85792238
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f55990d64dd01572c62993fb66276c21
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_24f5d006c7cce0106aaa1daceb00c58b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_007ce5db40e0eebc9b5f5a52a548469a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e032fb8552ee386cefb872a745f278c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7321-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a23a37868dfdb7c7190c850bf9168eb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a5b812ef05c5acbc749a370fe62c422
date 2022-04-21^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/35445392
https://doi.org/10.1111/bjh.18198
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1822
https://portal.issn.org/resource/ISSN/1365-2141
https://portal.issn.org/resource/ISSN/0007-1048
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA)
discusses http://id.nlm.nih.gov/mesh/M0585694
http://id.nlm.nih.gov/mesh/M000626416
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D006689Q000473
http://id.nlm.nih.gov/mesh/D000074322Q000627
http://id.nlm.nih.gov/mesh/D006689Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000077594Q000627
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D009364Q000188
http://id.nlm.nih.gov/mesh/D002908

Showing number of triples: 1 to 47 of 47.